Business
Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease
Virtual event on Tuesday, December 14, 2021, at 3 p.m. ET to discuss how the company’s differentiated gene correction approach using GPH101 could lead to
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"\nVirtual event on Tuesday, December 14, 2021, at 3 p.m. ET to discuss how the company’s differentiated gene correction approach using GPH101 could lead to curative outcomes\n\nWebinar to include an encore of the company’s poster presentation of the Phase 1/2 CEDAR Trial for GPH101 at the upcoming 63rd ASH Annual Meeting and Exposition\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nGraphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today that it will host a virtual Key Opinion Leader webinar on Tuesday, December 14, 2021, at 3 p.m. ET. The event will highlight Graphite Bio’s differentiated gene correction approach for sickle cell disease (SCD) using GPH101, the company’s lead investigational gene therapy; how GPH101 fits in the current gene therapy landscape; and GPH101’s potential to lead to curative outcomes in SCD.\n\nThe event will feature presentations by Josh Lehrer, M.Phil., M.D., chief executive officer at Graphite Bio, along with the following leading professionals in gene editing and SCD:\n\n\nMitchell J. Weiss, M.D., Ph.D., St. Jude Children’s Research Hospital, will provide an overview of the SCD gene therapy landscape.\n\n\nMatthew H. Porteus, M.D., Ph.D., Stanford University School of Medicine and academic founder of Graphite Bio, will discuss the foundational research for the company's differentiated gene correction approach for SCD.\n\n\nJulie Kanter, M.D., University of Alabama at Birmingham, will provide an encore of the company’s poster presentation of the Phase 1/2 CEDAR trial for GPH101 at the 63rd ASH Annual Meeting and Exposition. The original presentation will take place on Saturday, December 11, 2021, from 5:30-7:30 p.m. ET.\n\n\nJohn F. DiPersio, M.D., Ph.D., Washington University School of Medicine, will review the criteria for long-term cure in SCD.\n\n\nThe panelists will be available to answer questions following the formal presentations.\n\nThe event will be webcast live from Graphite Bio’s website at www.graphitebio.com in the Investors section. A replay of the webinar will be archived and available following the event.\n\nAbout Sickle Cell Disease (SCD)\n\nSCD is a serious, life-threatening inherited blood disorder that affects approximately 100,000 ...